Horizon Therapeutics Public Limited Company (HZNP) 銘柄情報

News: $HZNP Horizon Therapeutics PLC (HZNP) Q2 2020 Earnings Call Transcript

Image source: The Motley Fool. Horizon Therapeutics PLC   (NASDAQ: HZNP) Q2 2020 Earnings Call Aug 5, 2020 , 8:00 a.m. ET Operator Continue reading

Read the whole news HZNP - Horizon Therapeutics PLC (HZNP) Q2 2020 Earnings Call Transcript

News: $HZNP Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it is offering to sell $700,000,000 of its ordinary shares in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional $105,000,000 of ordinary shares in the...

In case you are interested HZNP - Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares

News: $HZNP Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance

-- Record Second-Quarter 2020 Net Sales of $462.8 Million Increased 44 Percent; Second-Quarter 2020 GAAP Net Loss of $80.0 Million; Adjusted EBITDA of $190.7 Million -- -- Quarterly Orphan Segment Net Sales Increased 87 Percent to $379.3 Million; Now Represents More Than 80 Percent o...

Got this from HZNP - Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance

I don't know if you know what you are talking about...

Hold on to it. Good one!

LC

HZNP

You pegged this one. I'm still in for the ride. More potential to come.

Strong uptrend again after the CV-19 downdraft.

LC

HZNP

Soon to be $50/share!

LC

HZNP

This one is in a strong uptrend.

LC

HZNP

Steady rising. $$$$$

Trading is halted pending outcome. Company already has infrastructure in place for sales. This is just a formality. It’s a keeper.

News: $HZNP Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance

-- Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million -- -- Quarterly Orphan and Rheumatology Segment Net Sales Increased 11 Percent to $223.5 Million; KRYSTEXXA ® Second-Quar...

Read the whole news Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance

Thought the earnings were good

Getting killed

Not!

Bottom is in

Down we go

* * $HZNP Video Chart 05-08-17 * *

Link to Video - click here to watch the technical chart video

Horizon Pharma Could Double Its Annual Sales Potential On This Near Term Catalyst http://marketexclusive.com/horizon-pharma-plc-nasdaqhznp-double-annual-sales-potential-near-term-catalyst/36480/?icd1

About 130 someone dumped a boatload of shares into the market. Probably paying for that acquisition.

They never fail to disappoint. Maybe eventually their growth will benefit shareholders.

Yeah, this thing makes those crazy moves on the regular. Some high fives under the table and champagne baths somewhere. Still solid play.

What News?

Wouldn't it be nice if we all could get the news that moved this stock all at the same time. Someone or some group knows something and I ain't in the loop. Then again, as my wife says, it's all rigged... so there's that.

GLTA

Boy she kicked the bucket after lunch today. Timberrrr.

This thing has been in the $30's with less prospect than it has now. We shall see.

Upward and Onward the chart goes!

Pop goes the weasel ... splat goes HZNP.

Nice pop here this morning

You just have to google it... the rumor is real

Hearing rumors about Horizon buying out Pernix Therapeutics. Anyone here know anything about that?

Yeah, we knew it wouldn't stay for long, but really shouldn't have been there in the first place. Even crazier that 10% of the float traded down. The oppressive pressure on the stock surely has to end eventually right? The stock really should be above $20, but seems to be lines ready to sell before then. Now we wait....again.

Were you saying something ?

With so little Brexit exposure, this thing is mopping the floor. What a turd.

Excellent consolidation

Yeah, I loaded the boat when it dropped. I was a little nervous for a bit, but the model is valid and has potential for a lot of growth.

21 next stop

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Three Additional Notices of Allowance With Claims Covering PENNSAID(R) (diclofenac sodium topical solution) 2% w/w

HZNP UBS Notes Several Positive Takeaways Following Horizon Pharma (HZNP) April 19, 2016 8:41 AM EDT

http://stockcharts.com/h-sc/ui?s=HZNP

Get Alerts HZNP Hot Sheet
Price: $14.52 +0.35%

Rating Summary:
12 Buy, 1 Hold, 1 Sell

UBS analyst Marc Goodman reiterated a Buy rating and $24 price target on Horizon Pharma (NASDAQ: HZNP) and offered several takeaways following investor meetings with CBO, Bob Carey.

(1) Duexis\Vimovo saw a higher level of restrictive plans than expected (additional step edits) such that gross-to-nets in 1Q moved to the 78-79% range vs expectations of 70- 75%. Horizon has been managing the business to $450-500\Rx. It will be lower in 1Q, and mgt would go lower on ASPs in return for volumes. Usually mgt assumes about a mid-single digit increase in payer control each year, but in 2016, it is seeing a step-wise change and it will be in double digits.

(2) Mgt acknowledges that HorizonCares has worked well the past 3 years, but it is always evaluating the changes needed for the primary care b-model to be successful for the next 3 years. Mgt seems more open to change than we have heard before.

(3) Upside areas include (a) Pennsaid as vols are running better than expected, (b) Krystexxa (the $70-80M guidance was a conservative assumption that didn't include any growth off the current runrate) that will have increased support moving forward (15-20 people up to 95 reps\special account managers), and (c) mgt admits there was a cushion in the original guidance.

(4) Mgt has increased focus on Pennsaid and has now made it the #1 detail for the 375 (up from 325 last year) primary care sales reps, as Pennsaid is more profitable with lower GtNs and no royalties relative to Duexis/Vimovo.

(5) M&A focus is (a) already- commercialized orphan products; (b) development-stage orphan products - mgt sounds much more focused here than it was a year ago; (c) specialty assets; and then (d) primary care assets. Mgt is seeing more activity today than before, but there is still a disconnect on value by the mgt teams at other companies.

(6) Mgt acknowledges that investors' attitudes towards leverage have changed. A year ago mgt was comfortable with its gross leverage ratio above 5x; now it would like to stay <4x.

(7) On Ravicti, Horizon has just gotten going in Canada and hired 3 reps. However, it doesn't sound like it is as focused on building out a footprint in Europe, as the economics don't seem to make sense.

For an analyst ratings summary and ratings history on Horizon Pharma click here. For more ratings news on Horizon Pharma click here.

Shares of Horizon Pharma closed at $15.04 yesterday.

HZNP 5 Stock Buys with Impressive Price-to-Cash Flow Ratios
April 19, 2016, 01:17:00 PM EDT By Zacks Equity Research, Zacks.com Comment


Shutterstock photo
"It is far better to buy a wonderful company at a fair price than a fair company at a wonderful price." - Warren Buffet.

Investment in stocks made on diligent value analysis is usually considered one of the best practices. It is always safest to look for the intrinsic value of stocks that are backed by sound fundamentals.

For an effective value investing, we would suggest considering Price to Cash Flow (or P/CF) ratio as one of the key metrics.

This metric evaluates the market price of the stock relative to the amount of cash flow that the company is generating on a per-share basis. One of the important factors that gives P/CF an upper hand is that operating cash flow adds back non-cash charges such as depreciation and amortization to net income, reflecting the true financial health of the company.

However, an investment decision solely based on P/CF metric may not fetch you the desired results. To identify stocks that are trading at a discount you should expand your search criteria and take into account price-to-book ratio, price-to-earnings ratio and price-to-sales ratio. Adding a favorable Zacks Rank and a Value Score of "A" or "B" to your search criteria should give you event better results, as they eliminate the chance of entering into a value trap.

The Bargain Hunting Strategy

The concept is that you have to target those stocks that are trading below their fair value. These stocks are actually trading at a bargain price and could fetch higher returns in the future. Let's quickly go through the parameters for selecting true value stocks before running the screen.

P/CF less than or equal to X-Industry Median remains our first parameter.

Price greater than or equal to 5: The stocks must all be trading at a minimum of $5 or higher.

Average 20-Day Volume greater than 100,000: A substantial trading volume ensures that the stock is easily tradable.

P/E using (F1) less than or equal to X-Industry Median: This parameter shortlists stocks that are trading at a discount or equal to their peers.

P/B less than or equal to X-Industry Median: A lower P/B compared with the industry average implies that there is enough room for the stock to gain.

P/S less than or equal to X-Industry Median: The P/S ratio determines how a stock price compares to its sales, lower the ratio the more attractive the stock.

PEG less than 1: The ratio is used to conclude a stock's value by taking the company's earnings growth into account. PEG ratio portrays a more complete picture than the P/E ratio, and a value of less than 1 indicates that stock is undervalued and investors need to pay less for a stock that has robust earnings growth prospect.

Zacks Rank less than or equal to 2: Zacks Rank #1 (Strong Buy) or 2 (Buy) stocks are known to outperform irrespective of the market environment.

Value Score of less than or equal to B: Our research shows that stocks with a Style Score of A or B when combined with a Zacks Rank #1 or 2 offer the best upside potential.

Here are five of the 12 stocks that qualified the screening:

Ascena Retail Group Inc. (ASNA)

Kirkland's Inc. (KIRK)

HomeStreet, Inc. (HMST)

Hersha Hospitality Trust (HT)

Horizon Pharma plc (HZNP)


Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

Disclosure: Performance information for Zacks' portfolios and strategies are available at: zacks.com

Short covering augmenting the continuing recovery...

HZNP Thomson Reuters/Verus upgrades HORIZON PHARMA PLC from HOLD to BUY.
BY Investars Analyst Actions - public
— 12:09 PM ET 04/18/2016

16.50 next stop

This was/is a safe play to stack for out sized profits.

Lot of up left, me thinks

I was ready and it's steady Eddy!

Would love to stay and watch the $$ printing machine but I's got work to do

Now you just continue on up, HZNP and I'll see you EOD.

Easy money back to 15

HZNP Chugging back up this morning.
Ridiculous drop yesterday, imo
Co reiterated guidance
Trade not appreciating numbers will almost always be higher in back end for juggernauts.
Easy peasy, me thinks

So where's the horizon now

Lucky

Sold 14.96. Lowered guidance not got for traders

Lowered guidance. It always bounces back